Q&A Open Orphan Directors increase holdings in company (LON:ORPH)

Open Orphan plc (LON:ORPH) CEO Cathal Friel joined DirectorsTalk Managing Director Darren Turgel to discuss progress on a number of fronts.

Q. Great to see today you increased your holdings in Open Orphan? 

A. I am delighted to have now had the opportunity to increase my personal stake in Open Orphan plc by today purchasing £300,000 worth of additional shares i.e. two times my annual salary. I am equally pleased that Brendan is joining me in doing likewise. These share purchases further demonstrates my and the Board’s commitment to the Company, and reiterates my confidence in Open Orphan’s future prospects as we enter a period where the infectious disease market is rapidly expanding and expected to grow to in excess of $250bn per annum by 2025.

Q. How is the pipeline for new contract wins looking?

A. We continue to roll out new contract wins and having signed and announced this week and last week, two significant challenge study contract wins for our London office and earlier today a €900k contract win for our Breda, Netherlands office.

Q. How are you looking on the financial side, are you still on target?

A. In the past week I was also delighted to confirm that we were solidly EBITDA profitable in H1 2021 and remain on target for a profitable and successful 2021.

Q. Previously you talked about spinning off non-core assets, how are you progressing?

A. Likewise, earlier today Poolbeg Pharma plc filed its Schedule One confirming that it had successfully raised £25m in fresh funds on a pre-money valuation of £25m, thus when it completes its IPO in the coming week it should be listing with a market cap of c. £50m. This is an excellent start to our strategy of spinning off and monetizing our non-core assets. We plan and expect to spin off the other three non-core assets between now and year end; namely our 49% stake in Imutex, our 62.6% stake in PrEP Biopharm and Disease in Motion platform business. Thus, we have a very exciting year ahead for Open Orphan.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Non-Clinical Development

Non-clinical testing is conducted throughout all phases of drug development to assess the safety profile and pharmacokinetic/toxicokinetic (PK/TK) characteristics of drug candidates. If performed well, it can identify key ‘knock-out’ criteria early, maximizing the chances of success in

Open Orphan Plc

Open Orphan pharmaceutical company expands Covid-19 trial

Pharmaceutical services company Open Orphan is expanding its Covid-19 challenge study, inoculating up to 20 further volunteers. The government-funded trial, which is being carried out with subsidiary hVivo, involves deliberately infecting people with Covid in a controlled setting to see

Open Orphan Plc

Open Orphan subsidiary signs contract for antiviral study

Clinical research organisation (CRO) Open Orphan has announced that its subsidiary hVIVO has signed a contract with AIM ImmunoTech to test its antiviral candidate, Ampligen, against the human Rhinovirus HRV, or common cold, and influenza, in a single

Open Orphan Plc

Open Orphan signs significant contract with AIM IT to test Ampligen

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed

Open Orphan Plc

Don’t be afraid of the FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It is the US Agency responsible for the regulation of drugs and biologics, including, vaccines for humans, blood and blood

Open Orphan Plc

Open Orphan launches infectious disease spinout

Clinical research organisation (CRO) Open Orphan has launched a spin-out organisation targeting the infectious disease market. Biotech Poolbeg Pharma has been created in the wake of the Covid-19 pandemic and builds upon Open Orphan’s experience and knowledge of

Open Orphan Plc

Open Orphan on Covid-19 and studying the virus

The MedTalk’s Reece Armstrong speaks to Cathal Friel, chairman and co-founder of Open Orphan, about the company’s involvement in setting up the first human challenge study model for Covid-19 and the importance of studying the virus during the